000125453 001__ 125453
000125453 005__ 20240228143308.0
000125453 0247_ $$2doi$$a10.1158/0008-5472.CAN-16-1123
000125453 0247_ $$2pmid$$apmid:27197228
000125453 0247_ $$2ISSN$$a0008-5472
000125453 0247_ $$2ISSN$$a0099-7013
000125453 0247_ $$2ISSN$$a0099-7374
000125453 0247_ $$2ISSN$$a1538-7445
000125453 0247_ $$2altmetric$$aaltmetric:7372514
000125453 037__ $$aDKFZ-2017-01582
000125453 041__ $$aeng
000125453 082__ $$a610
000125453 1001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b0$$eLast author$$udkfz
000125453 245__ $$aCommentary on Folkman: 'How Is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?'.
000125453 260__ $$aPhiladelphia, Pa.$$bAACR$$c2016
000125453 3367_ $$2DRIVER$$aarticle
000125453 3367_ $$2DataCite$$aOutput Types/Journal article
000125453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521117558_30678$$xReview Article
000125453 3367_ $$2BibTeX$$aARTICLE
000125453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125453 3367_ $$00$$2EndNote$$aJournal Article
000125453 520__ $$aAngiogenesis is a prerequisite for tumor growth and metastatic progression. The discovery of the first specific angiogenic cytokine, VEGF, in 1989 paved the way for the clinical approval of the first antiangiogenic tumor drug 15 years later. This brief commentary highlights and puts into historical perspective the 1985 G.H.A. Clowes Memorial Award Lecture delivered by Dr. Judah Folkman. Thirty years later, this award lecture is a lively testimony of the visionary mind of Dr. Folkman, whose legacy continues to inspire contemporary angiogenesis research. Cancer Res; 76(10); 2854-6. ©2016 AACRSee related article by Folkman J, Cancer Res 1986;46:467-73.
000125453 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000125453 588__ $$aDataset connected to CrossRef, PubMed,
000125453 650_7 $$2NLM Chemicals$$aAngiogenesis Inhibitors
000125453 773__ $$0PERI:(DE-600)2036785-5$$a10.1158/0008-5472.CAN-16-1123$$gVol. 76, no. 10, p. 2854 - 2856$$n10$$p2854 - 2856$$tCancer research$$v76$$x1538-7445$$y2016
000125453 909CO $$ooai:inrepo02.dkfz.de:125453$$pVDB
000125453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125453 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000125453 9141_ $$y2016
000125453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER RES : 2015
000125453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125453 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125453 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125453 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125453 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125453 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125453 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125453 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125453 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125453 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER RES : 2015
000125453 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lVaskuläre Onkologie und Metastasierung$$x0
000125453 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000125453 980__ $$ajournal
000125453 980__ $$aVDB
000125453 980__ $$aI:(DE-He78)A190-20160331
000125453 980__ $$aI:(DE-He78)L101-20160331
000125453 980__ $$aUNRESTRICTED